Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients

被引：0
|
作者：
Garziera, M. [1 ]
Cecchin, E. [1 ]
Montico, M. [1 ]
Roncato, R. [1 ]
Gagno, S. [1 ]
De Mattia, E. [1 ]
Sorio, R. [2 ]
Scalone, S. [2 ]
Poletto, E. [3 ]
Toffoli, G. [1 ]
机构：
[1] Natl Canc Inst, CRO, Expt & Clin Pharmacol Unit, Aviano, Italy
[2] Natl Canc Inst, CRO, Oncol Unit C, Aviano, Italy
[3] Univ Udine, Dept Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer (HGSOC)
    LaVigne, K.
    Benhamida, J.
    Young, J.
    Zivanovic, O.
    Chi, D. S.
    Snyder, A.
    Hollmann, T.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 76 - 76
  • [2] DETECTION AND CHARACTERIZATION OF P53 PRIONS IN HIGH-GRADE SEROUS OVARIAN CANCER
    Heinzl, N.
    Maritschnegg, E.
    Koziel, K.
    Horvat, R.
    Sehouli, J.
    Braicu, I.
    Vergote, I.
    van Nieuwenhuysen, E.
    Mahner, S.
    Obermayr, E.
    Schuster, E.
    Holzer, B.
    Concin, N.
    Zeillinger, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1521 - 1521
  • [3] DETECTION AND CHARACTERIZATION OF P53 PRIONS IN HIGH-GRADE SEROUS OVARIAN CANCER
    Heinzl, N.
    Maritschnegg, E.
    Koziel, K.
    Horvat, R.
    Sehouli, J.
    Braicu, I.
    Vergote, I.
    van Nieuwenhuysen, E.
    Mahner, S.
    Obermayr, E.
    Schuster, E.
    Holzer, B.
    Concin, N.
    Zeillinger, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 298 - 298
  • [4] P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.
    Mandilaras, Victoria
    Garg, Swati
    Burnier, Julia
    Karakasis, Katherine
    Wang, Lisa
    Mackay, Helen
    Dhani, Neesha C.
    Butler, Marcus O.
    Rodriguez-Freixinos, Victor
    Wilson, Michelle K.
    Martin-Lorente, Cristina
    Ethier, Josee-Lyne
    Bedard, Philippe L.
    Siu, Lillian L.
    Clarke, Blaise
    Shaw, Patricia Ann
    Stockley, Tracy
    Oza, Amit M.
    Lheureux, Stephanie
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer
    Park, Eunhyang
    Han, Hyunho
    Choi, Sung-Eun
    Park, Hyunjin
    Woo, Ha-Young
    Jang, Mi
    Shim, Hyo-Sup
    Hwang, Sohyun
    Kang, Haeyoun
    Cho, Nam-Hoon
    DIAGNOSTICS, 2022, 12 (03)
  • [6] High-grade serous ovarian cancer (HGSOC) with fallopian tube involvement
    Tanase, Adina Elena
    Solomon-condriuc, Iustina Petra
    Mogos, Raluca Anamaria
    Costachescu, Gabriel
    David, Cristina
    Buzduga, Catalin Mihai
    Scripcariu, Dragos Viorel
    Costea, Claudia Florida
    Cucu, Andrei Ionut
    Tanase, Gabriel Valentin
    Tanase, Daniela Maria
    Nemescu, Dragos
    Dumitrescu, Ana Maria
    Carauleanu, Alexandru
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2024, 65 (02): : 325 - 329
  • [7] Prognostic impact of the humoral immune response against p53 protein in advanced epithelial ovarian cancer
    Zeimet, AG
    Abendstein, B
    Widschwendter, M
    Müller-Holzner, E
    Marth, C
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 341 - 345
  • [8] Clinical outcomes of immunohistochemistry of the p53 staining pattern in high-grade serous ovarian carcinoma
    Orachum, Panarat
    Temtanakitpaisan, Amornrat
    Kleebkaow, Pilaiwan
    Chumworathayi, Bandit
    Luanratanakorn, Sanguanchoke
    Aue-angkul, Apiwat
    Itarat, Yuwadee
    OBSTETRICS & GYNECOLOGY SCIENCE, 2022, 65 (05) : 459 - 467
  • [9] Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
    Hayano, Takahide
    Yokota, Yuki
    Hosomichi, Kazuyoshi
    Nakaoka, Hirofumi
    Yoshihara, Kosuke
    Adachi, Sosuke
    Kashima, Katsunori
    Tsuda, Hitoshi
    Moriya, Takuya
    Tanaka, Kenichi
    Enomoto, Takayuki
    Inoue, Ituro
    PLOS ONE, 2014, 9 (12):
  • [10] Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.
    Gourley, Charlie
    McCavigan, Andrena
    Perren, Timothy
    Paul, James
    Michie, Caroline Ogilvie
    Churchman, Michael
    Williams, Alistair
    McCluggage, W. Glenn
    Parmar, Mahesh
    Kaplan, Richard S.
    Hill, Laura A.
    Haifpenny, Iris A.
    O'Brien, Earnonn J.
    Raji, Olaide
    Deharo, Steve
    Davison, Timothy
    Johnston, Patrick
    Keating, Katherine E.
    Harkin, D. Paul
    Kennedy, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345